The role of CYP2D6 in primary and secondary oxidative metabolism of dextromethorphan: in vitro studies using human liver microsomes
about
Methadone N-demethylation in human liver microsomes: lack of stereoselectivity and involvement of CYP3A4Development of a rapid and sensitive high-performance liquid chromatographic method to determine CYP2D6 phenotype in human liver microsomes.Summary of information on human CYP enzymes: human P450 metabolism data.Prediction of relative in vivo metabolite exposure from in vitro data using two model drugs: dextromethorphan and omeprazole.The influence of CYP2D6 polymorphism and quinidine on the disposition and antitussive effect of dextromethorphan in humans.Ontogeny of dextromethorphan O- and N-demethylation in the first year of life.Modulation of CYP2D6 and CYP3A4 metabolic activities by Ferula asafetida resinComputational predictions of the site of metabolism of cytochrome P450 2D6 substrates: comparative analysis, molecular docking, bioactivation and toxicological implications.A discordance between cytochrome P450 2D6 genotype and phenotype in patients undergoing methadone maintenance treatment.Concentration-time profile for perhexiline and hydroxyperhexiline in patients at steady stateClinical inhibition of CYP2D6-catalysed metabolism by the antianginal agent perhexiline.Comparison of (S)-mephenytoin and proguanil oxidation in vitro: contribution of several CYP isoforms.Methadone inhibits CYP2D6 and UGT2B7/2B4 in vivo: a study using codeine in methadone- and buprenorphine-maintained subjects.Developmental toxicity of dextromethorphan in zebrafish embryos/larvae.Role of human liver microsomes in in vitro metabolism of drugs-a review.Chemical inhibitors of cytochrome P450 isoforms in human liver microsomes: a re-evaluation of P450 isoform selectivity.Expression in human prostate of drug- and carcinogen-metabolizing enzymes: association with prostate cancer risk.Effect of methamphetamine on the pharmacokinetics of dextromethorphan and midazolam in rats.Predicting drug clearance from recombinantly expressed CYPs: intersystem extrapolation factors.In vitro assessment of human cytochrome P450.Interpatient variability: genetic predisposition and other genetic factors.Pharmacokinetics of the antianginal agent perhexiline: relationship between metabolic ratio and steady-state dose.CYP3A5 but not CYP2D6 polymorphism contributes significantly to the variability in dextropropoxyphene disposition.Using a homology model of cytochrome P450 2D6 to predict substrate site of metabolism.The effects of concomitant administration of theophylline and toborinone on the pharmacokinetics of both compounds in poor and extensive metabolizers via CYP2D6.Comparative study of the metabolism of drug substrates by human cytochrome P450 3A4 expressed in bacterial, yeast and human lymphoblastoid cells.Analysis of pharmacokinetic parameters for assessment of dextromethorphan metabolic phenotypes.Bioengineered humanized livers as better three-dimensional drug testing model system.Understanding the relative roles of pharmacogenetics and ontogeny in pediatric drug development and regulatory science.In vitro inhibitory effects of Wen-pi-tang-Hab-Wu-ling-san on human cytochrome P450 isoforms.
P2860
Q24564971-4C63E260-B098-4E06-890D-28DD21D8F363Q31036625-865DF4BC-E417-4C29-8FEB-89EAD3B119B4Q32103802-70BA3C18-1B75-4F68-9037-24657FD68A99Q34051253-6E2EF698-C4B0-4678-A55D-3EB8C225CF40Q34400605-5CC9EC65-4FE2-4475-B7A8-8E4C0674DEE6Q34575597-AE29F9C2-48F2-4751-A7BB-73BAF07BA6ADQ34800242-8F6EB2CF-5025-4AB1-BADF-51E2CE7E54ADQ35646205-06D26D75-7D78-4CD8-BA5D-14586229FAF0Q35825489-E3D5B257-ED2E-49D6-B0C4-1FE974CBED23Q35825990-2E06467E-4741-43E8-9489-356F30005CE3Q35826004-3C9559E2-316C-471C-8329-2D20F18FA7A0Q36053568-4FC1BB17-05A6-4FB4-BBC8-FBE8EEE6E44AQ36111225-139AD5AE-453C-40D1-A364-7A556A80AF1AQ36449529-45137A82-1B30-4A19-818F-64835776328DQ37543206-CC56DD39-7F55-4352-A2CF-D9B496E0EF79Q37845170-D14ACA54-FEC9-4119-93FC-A47316CBC023Q39710934-DDFB6901-2F40-470E-8718-A1C9C1D44726Q40377837-37F29851-8A57-42C6-BDE1-76D13D5B965CQ40529215-9E185577-30DB-44B9-B075-F94E42758DC2Q40828743-161C49C6-292D-4908-8F1D-65C1B66C99F0Q41550904-5330B005-2BCB-4D9E-AE57-C208C36ACE0BQ42125291-89F18A17-09E5-46A8-9371-C6EB846A9373Q43172642-C7B4CDE8-379F-4B59-BF8E-9B058B75D6ABQ43892219-ABD36948-1947-47E2-93A4-422DB6BD3A45Q43997702-E17A18E3-054E-4F5E-A978-A0E5CEEA88CDQ44252903-46D24DA0-EE7E-4F56-855B-F3C4F2691D05Q44556138-D22CCFCA-4EDC-4514-928A-AFD3DE6DB6A5Q49334387-556A46CD-3B3A-4F34-B644-8BB3F115E8ABQ50707361-64423E7B-15B2-4B95-B574-52D859EDD4F9Q53417029-8D240B8D-C92C-4CD5-A7D9-4CED4DD5A2EC
P2860
The role of CYP2D6 in primary and secondary oxidative metabolism of dextromethorphan: in vitro studies using human liver microsomes
description
1994 nî lūn-bûn
@nan
1994 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
1994 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
1994年の論文
@ja
1994年論文
@yue
1994年論文
@zh-hant
1994年論文
@zh-hk
1994年論文
@zh-mo
1994年論文
@zh-tw
1994年论文
@wuu
name
The role of CYP2D6 in primary ...... s using human liver microsomes
@ast
The role of CYP2D6 in primary ...... s using human liver microsomes
@en
The role of CYP2D6 in primary ...... s using human liver microsomes
@nl
type
label
The role of CYP2D6 in primary ...... s using human liver microsomes
@ast
The role of CYP2D6 in primary ...... s using human liver microsomes
@en
The role of CYP2D6 in primary ...... s using human liver microsomes
@nl
prefLabel
The role of CYP2D6 in primary ...... s using human liver microsomes
@ast
The role of CYP2D6 in primary ...... s using human liver microsomes
@en
The role of CYP2D6 in primary ...... s using human liver microsomes
@nl
P2093
P2860
P1476
The role of CYP2D6 in primary ...... s using human liver microsomes
@en
P2093
P2860
P304
P356
10.1111/J.1365-2125.1994.TB04348.X
P407
P50
P577
1994-09-01T00:00:00Z